Literature DB >> 10573782

Subtypes in monosymptomatic nocturnal enuresis. II.

J D van Gool1, E Nieuwenhuis, I O ten Doeschate, T P Messer, T P de Jong.   

Abstract

Lasting cure rates in monosymptomatic nocturnal enuresis (MNE), using the alarm, imipramine or desmopressin, have been quoted as 43%, 17% and 22%, respectively. The low cure rates in addition to the number of different treatments indicate insufficient knowledge of MNE. Only research on arginine vasopressin (AVP) levels and nocturnal enuresis is unique in attempting to find a group within the MNE population that could benefit from substitution therapy with desmopressin. AVP levels are restored or amplified during desmopressin treatment. However, low nocturnal AVP production with high nocturnal urine output may be indicative of a disturbance in circadian rhythm. Pre-clinical data suggest a role for melatonin in the regulation of endogenous AVP and in the regulation of the sleep/wake cycle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10573782     DOI: 10.1080/00365599950510094

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  3 in total

Review 1.  Current perspectives on the correlation of nocturnal enuresis with obstructive sleep apnea in children.

Authors:  Miao-Shang Su; Li Xu; Wen-Feng Pan; Chang-Chong Li
Journal:  World J Pediatr       Date:  2018-11-16       Impact factor: 2.764

2.  Prevalence and risk factors of monosymptomatic nocturnal enuresis in Turkish children.

Authors:  Seçil Ozkan; Elif Durukan; Elvan Iseri; Serhat Gürocak; Işil Maral; M Ali Bumin
Journal:  Indian J Urol       Date:  2010-04

3.  Melatonin's Effect on the Efficacy of Desmopressin in the Treatment of Enuresis.

Authors:  Pietro Ferrara; Annamaria Sbordone; Costanza Cutrona; Francesca Ianniello; Chiara Guadagno; Giacomo Perrone; Antonio Chiaretti; Alberto Verrotti; Vincenzo Di Lazzaro
Journal:  Int Neurourol J       Date:  2016-09-23       Impact factor: 2.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.